MedTrace Logo

Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting

NCT02037737 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 153

Last updated 2018-02-07

No results posted yet for this study

Summary

The purpose of this study is to assess Abatacept Intravenous (IV) effectiveness in patients with inadequate response to one or more conventional Disease Modifying Against Rheumatism (DMARDs) including Methotrexate in France, through the estimation of Abatacept retention rate over 2 years and reasons of discontinuation

Conditions

Interventions

DRUG

Abatacept

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2018-01-31
Completion
2018-01-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02037737 on ClinicalTrials.gov